samedan logo
 
 
 
spacer
home > ebr > spring 2003 > biotech companies in the pharma market - grow or be doomed, warns dr volker janssen, director at simon-kucher & partners
PUBLICATIONS
European Biopharmaceutical Review

Biotech Companies in the Pharma Market - Grow or be Doomed, warns Dr Volker Janssen, Director at Simon-Kucher & Partners

The German biotech industry is booming. According to a study carried out by management consultancy Ernst & Young, the number of biotech companies with less than 500 employees (this accounts for the majority of German biotechs) increased by more than 90 per cent between 1997 and 2000, which means there are now more than 300 biotech companies operating in Germany. The turnover generated by these companies has nearly tripled, as has the number of employees. In 2000, the Biotech Index on the Neuer Markt in Frankfurt was often quoted at 50 per cent above the NEMAX Allshare Index. In view of Germany's unparalleled growth in the biotech arena one was inclined to believe Deutsche Bank's forecasts for the sector: a turnover increase for SME

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Volker Janssen, Director at Simon-Kucher & Partners

Dr Volker Janssen is a Director in the Life Science division of Simon-Kucher & Partners Strategy & Marketing Consultants. He specialises in consulting to pharmaceutical clients, mainly in the areas of strategic marketing, corporate communications, sales force management, market segmentation, international pricing and value-to-customer.

He has worked for a number of companies in Europe, Japan and the US, including Aventis, Pfizer, Novo Nordisk, Fujisawa, Johnson & Johnson, Eli Lilly, 3M, Sanitec and DHL. Dr Janssen is the author of numerous publications on pricing, sales force management and communication and has spoken frequently at conferences and seminars on these subjects.

spacer
Dr Volker Janssen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement